Entrepreneur of next-gen gene therapy

| | January 30, 2014
This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

If you’re in the business of drug discovery, you’ve got to be ready for the long haul. One recent study published in Nature Biotechnology suggested that only around 10% of drug indications that enter clinical trials ever reach FDA clearance.

So it takes a special kind of chutzpah to start a company around a type of treatment that has never met with FDA approval. Yet the founders of Editas Medicine, based in Cambridge, MA, are optimistic that now is the time to enter the business of gene therapy – almost a quarter century after the first clinical trials of gene therapy in the U.S. began, without producing a single commercial product to this day.

Read the full, original story: Gene Therapy’s Next Generation


Share via
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.
Send this to a friend